H.R. 1082Passed one chamberHealth care
Bill sets fines up to $20,000 for tissue product safety violations
Data as of July 22, 2026
HR 1082 adds fines and FDA transparency rules for human tissue products like donated skin, bone, and tendons.AI-decoded40-second read · 5 questions answered below
Decoded
AI-decodedWhat does this do?
The bill requires HHS to run a public education campaign on the risks, benefits, and screening of human cell and tissue products. It also creates financial penalties for safety rule violations and directs the FDA to publish more information about inspections and facility oversight, plus report to Congress by September 2026.
Who does it affect?
Patients receiving tissue-based treatments, healthcare providers, tissue banks and processing companies, and FDA regulatory staff are affected.
Why does it matter?
The changes aim to hold tissue processors accountable for safety lapses and give patients, providers, and Congress clearer information about how the industry is regulated.
What does it cost, and who pays?
- Fines up to $20,000 per violation
- Extra daily penalties possible
- Repayment capped at $10 million per case
Where does it stand?
- Introduced
- House committee
- House vote
- Senate — You are here
- President's desk
Right now: it passed the House and now goes to the Senate. If the Senate changes it, it goes back to the House before reaching the President.
AI-drafted summary. Verify it against the official text before you act on it.
Make the call
Three steps: where you stand, your script, the call.
See how a call works
Official title
Shandra Eisenga Human Cell and Tissue Product Safety Act
- Introduced:
- February 6, 2025
- Latest action:
- June 24, 2025
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Read the official bill on Congress.gov